Literature DB >> 7396313

Amantadine hydrochloride pharmacokinetics in hemodialysis patients.

L S Soung, T S Ing, J T Daugirdas, M J Wu, V C Gandhi, P T Ivanovich, J E Hano, G W Viol.   

Abstract

To study the fate of amantadine hydrochloride in patients with renal failure, we gave 100 mg orally to 12 such patients immediately after hemodialysis. Plasma levels did not decrease between 24 and 44 hours after drug ingestion, suggesting an extremely poor total body clearance. Apparent volume of distribution was 5.1 +/- 0.2 (SEM) L/kg of body weight. Between 44 and 48 hours, as a result of 4 hours of hemodialysis, the mean plasma drug level decreased from 268 to 225 ng/mL (P less than 0.001). Dialyzer clearance was 67.0 +/- 3.9 mL of plasma per minute. The total quantity of drug removed by the dialysis treatment, however, was only 3.9 +/- 0.25 mg. The average half-life of amantadine in eight patients studied while receiving maintenance hemodialysis was 24.3 +/- 2.4 h of dialysis administered over approximately 13 days. Plasma half-life in six nonuremic control subjects was 12.2 +/- 1.6 h. Amantadine is poorly excreted in dialysis patients and has a large volume of distribution. The amount removed by a single dialysis is only a small fraction of the total body store.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7396313     DOI: 10.7326/0003-4819-93-1-46

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

3.  Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults.

Authors:  F G Hayden; A Minocha; D A Spyker; H E Hoffman
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

4.  Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics.

Authors:  F G Hayden; H E Hoffman; D A Spyker
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of amantadine hydrochloride.

Authors:  F Y Aoki; D S Sitar
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

Review 6.  Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.

Authors:  D R Guay
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

7.  Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets.

Authors:  Tina deVries; Angela Dentiste; Clifford Di Lea; Vincent Pichette; David Jacobs
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

8.  Acute respiratory distress syndrome: A rare presentation of amantadine toxicity.

Authors:  Juan Cattoni; Ravish Parekh
Journal:  Am J Case Rep       Date:  2014-01-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.